Telisotuzumab vedotin-tllv (Emrelis)
Reconstitution and dilutionFull monograph review pending
U.S. label preparation
Emrelis · Reconstitution and dilution
- Preparation
- Reconstitute with sterile water for injection using the vial-specific volume in Table 4 (20 mg/mL). For the infusion, dilute only in 0.9% sodium chloride to 1-10 mg/mL.
- Administration and handling
- Use the appropriate handling precautions for the cytotoxic component.
Product and source details
AbbVie Inc. · BLA761384
Product NDC: 0074-1044, 0074-1055
SPL effective 2025-05-25 | SPL version 3. Checked 2026-11-13.
Source for this summary: U.S. prescribing information. Use the full label for dose selection, contraindications, preparation tables and monitoring.
Product identifiers and clinical review status
U.S. label preparation available. Full monograph review pending.
Exact formulation, concentration, container, manufacturer, regulatory identifiers, and a reproducible label snapshot have not all been reconciled.
What remains to be completed
- Obtain independent corroboration of the label preparation where available.
- Complete indication- and age-specific dosing, incompatibility, monitoring and stability review.
- Assess any proposed compounding BUD for the exact formulation, concentration, container and conditions.